Akèy › Kansè renn (Kasinom selil renn) › Michigan
Etid klinik pou Kansè renn (Kasinom selil renn) nan Michigan
29 etid pou Kansè renn (Kasinom selil renn) ap chèche patisipan nan sit nan Michigan.
Vil nan Michigan
- Ann Arbor12 etid
- Detroit10 etid
- Grand Rapids10 etid
- Canton5 etid
- Livonia5 etid
- Lansing4 etid
- Dearborn4 etid
- Warren3 etid
- Waterford3 etid
- Farmington Hills3 etid
- Flint3 etid
- Troy3 etid
- Wyoming3 etid
- Kalamazoo3 etid
Tèks ofisyèl etid la (Anglè)
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
- Research Site, Detroit
- Research Site, Detroit
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Oct 5, 2026 · NCT05536141Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
- NEO-811 Grand Rapids Site, Grand Rapids
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Oct 5, 2026 · NCT07300241A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- South Texas Accelerated Research Therapeutics (START), Grand Rapids
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT06270706Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- MyMichigan Medical Center Gratiot, Alma
- MyMichigan Medical Center Alpena, Alpena
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- ak 68 plis
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 40 a 75 · Tout sèks · Mizajou Oct 2, 2026 · NCT05334069Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #65, Detroit
- Exelixis Clinical Site #13, Detroit
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT05176483Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
- Trinity Health Medical Center - Brighton, Brighton
- ak 32 plis
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT03866382A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
- Local Institution - 0176, Big Rapids
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT07293351Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
- START Midwest, Grand Rapids
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 18, 2026 · NCT05267626Photodynamic Diagnosis of Kidney Cancer Using Fluorescence Endoscopy and Oral 5-ALA
- Henry Ford Health, Detroit
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 18, 2026 · NCT07828704Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- University of Michigan Rogel Cancer Center, Ann Arbor
- Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
- ak 12 plis
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 18, 2026 · NCT05327686A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
- University of Michigan, Ann Arbor
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT07195916ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- Cancer & Hematology Centers of Western Michigan, Grand Rapids
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT05059444Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
- Bronson Battle Creek, Battle Creek
- Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
- Trinity Health IHA Medical Group Hematology Oncology - Canton, Canton
- ak 17 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 2, 2026 · NCT06661720A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
- Research Site, Grand Rapids
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 19, 2026 · NCT07115043Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
- University of Michigan, Ann Arbor
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 18, 2026 · NCT06966024A Study of MGC026 in Participants With Advanced Solid Tumors
- START Midwest, Grand Rapids
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 11, 2026 · NCT06242470Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial
- University of Michigan Comprehensive Cancer Center, Ann Arbor
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jul 31, 2026 · NCT06866262Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
- Henry Ford Cancer Institute, Detroit
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jul 29, 2026 · NCT04198766A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
- Henry Ford Health, Detroit
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jul 9, 2026 · NCT03972657Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer
- Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
- Trinity Health IHA Medical Group Hematology Oncology - Canton, Canton
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea
- ak 2 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Jun 11, 2026 · NCT07383441KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
- Henry Ford Health System, Detroit
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jun 8, 2026 · NCT06026410Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
- University of Michigan Comprehensive Cancer Center Michigan Medicine /ID# 252010, Ann Arbor
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jun 4, 2026 · NCT04777994Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma
- University of Michigan, Ann Arbor
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou May 20, 2026 · NCT06053658A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
- Start Midwest Cancer Research, Grand Rapids
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Apr 28, 2026 · NCT06413680Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
- Henry Ford Cancer Institute, Detroit
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Dec 17, 2025 · NCT05856981A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
- University of Michigan Hospitals, Ann Arbor
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2025 · NCT06805825Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
- University of Michigan Comprehensive Cancer Center, Ann Arbor
- Bronson Battle Creek, Battle Creek
- University of Michigan - Brighton Center for Specialty Care, Brighton
- ak 15 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2025 · NCT04510597A Beta-only IL-2 ImmunoTherapY Study
- Karmanos Cancer Institute, Detroit
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jul 9, 2025 · NCT05086692A Study of IBI363 in Subjects with Advanced Solid Malignancies
- Michigan Hematology & Oncology Consultants - MedOnc Dearborn, Dearborn
- Michigan Hematology & Oncology Consultants - MedOnc Troy, Troy
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Dec 19, 2024 · NCT06281678Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.